Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-1971 in combination with osimertinib or cetuximab in NSCLC and CRC
NCT05954871Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of migoprotafib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (4 arms), sponsored by Genentech. Primary endpoints: Adverse Events at 41 months and Dose-Limiting Toxicities at 28 days. Started Jan 2024; status: completed.
02
Drugs
migoprotafib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05954871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954871.